← Leaderboards
W Brooks Gentry
University Of Arkansas Med Scis Ltl Rock
$28,446,095
Attributed
$52,184,552
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.5M · FY2009–23$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$52,184,552 · 11
By mechanism
U01$43,053,709 · 5
R01$4,181,137 · 2
RC2$3,964,137 · 1
K08$526,500 · 1
KL2$459,069 · 1
P01$0 · 1
Top collaborators
- Misty Ward Stevens16 shared
- R. Barry Holtz2 shared
- Elisabet Borsheim1 shared
Others in their field
Top investigators on “Methamphetamine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,285,082
- Xinhua Li · Nano Terra, Inc.$36,275,012
- Susan H Eshleman · Johns Hopkins University$29,811,957
- Steven Shoptaw · University Of California Los Angeles$26,075,817
- Tariq M Rana · Univ Of Med/Dent Nj-R W Johnson Med Sch$25,133,611
Research focus
MethamphetamineDosePharmaceutical PreparationsBrainDrug KineticsAffinityBloodDesignMonoclonal AntibodiesAntibodiesSafetyFutureStability TestingPreparationRattusClinical ResearchGrantReportingRelapseBehavior TherapySiteProtocols DocumentationResponseMedical
Grant awards (31)
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,609,902
U01 · FY2023 · DA
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,570,609
U01 · FY2022 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$1,863,102
U01 · FY2022 · DA
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,597,509
U01 · FY2021 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$3,750,210
U01 · FY2021 · DA
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,165,675
U01 · FY2021 · DA
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,136,427
U01 · FY2020 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$2,492,018
U01 · FY2020 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$1,429,307
U01 · FY2019 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$938,893
U01 · FY2019 · DA
Institutional Career Development$459,069
KL2 · FY2019 · TR · contact PI
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$2,735,856
U01 · FY2018 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$4,601,742
U01 · FY2017 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$194,975
U01 · FY2017 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$2,085,133
U01 · FY2016 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$1,594,873
U01 · FY2015 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$1,287,478
U01 · FY2014 · DA
First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody$94,668
R01 · FY2014 · DA · contact PI
First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody$531,474
R01 · FY2013 · DA · contact PI
First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody$1,087,525
R01 · FY2012 · DA · contact PI
First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody$1,405,591
R01 · FY2011 · DA · contact PI
Monoamine Antagonist Therapies for Methamphetamine Abuse$348,109
R01 · FY2011 · DA · contact PI
Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity$2,769,478
RC2 · FY2010 · DA
Monoamine Antagonist Therapies for Methamphetamine Abuse$358,875
R01 · FY2010 · DA · contact PI
Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity$1,194,659
RC2 · FY2009 · DA
Monoamine Antagonist Therapies for Methamphetamine Abuse$354,895
R01 · FY2009 · DA · contact PI
MECHANISMS OF ONSET &OFFSET OF RAPID STIMULANT EFFECTS$175,500
K08 · FY2002 · DA
Antibodies As Biological Interventions For Drug Abuse$0
P01 · FY2002 · DA
MECHANISMS OF ONSET &OFFSET OF RAPID STIMULANT EFFECTS$175,500
K08 · FY2001 · DA
Antibodies As Biological Interventions For Drug Abuse$0
P01 · FY2001 · DA
MECHANISMS OF ONSET &OFFSET OF RAPID STIMULANT EFFECTS$175,500
K08 · FY2000 · DA